Keep reading to discover more, as informed by medical experts and research to date
This decrease significantly mitigates the risk of future chronic weight-related illnesses
doi: 10.3389/fncel.2025.1601366 Received 27 March 2025 Accepted 10 June 2025 Published 04 July 2025 Volume 19 - 2025 Edited by Marco Cambiaghi, University of Verona, Italy Reviewed by Enoch Luis, National Council of Science and Technology (CONACYT), Mexico Mingzi Zhang, University of Southern California, United States Updates Copyright 2025 Bessetti and Litwa
In a phase 2 randomized clinical trial, it demonstrated a benefit in terms of resolution of MASH in patients with histologically proven MASH and stage 2 or 3 fibrosis. In his presentation, Newsome reported interim efficacy and safety results from the ongoing phase 3 ESSENCE trial, which is comparing once-weekly, subcutaneous semaglutide vs